ImmVira's Engineered Exosomes for Hair Growth and Fat Reduction Receive INCI Certification, Opening Path to Global Markets
核心洞察
ImmVira (搜索)'s engineered exosome products MVR-EX104 for alopecia treatment and MVR-EX105 for localized fat reduction have obtained INCI designations, marking a breakthrough in functional aesthetic ingredients.
The INCI certification serves as a universal "passport" for aesthetic ingredients across major markets including the US, EU, and Japan, enabling direct overseas market entry.
According to Frost and Sullivan projections, the global alopecia treatment market will reach $89.9 billion and localized adipose accumulation management market will reach $191.5 billion by 2033.
ImmVira (搜索) Group announced that its engineered exosome products MVR-EX104 for alopecia treatment and MVR-EX105 for localized fat accumulation have obtained International Nomenclature of Cosmetic Ingredients (INCI) designations following review by the International Cosmetic Ingredient Nomenclature Committee. This dual milestone positions ImmVira as a pioneer in functional aesthetic ingredients and opens access to substantial aging-related market opportunities.
Breakthrough Technology Platform
The engineered exosomes are developed using ImmVira (搜索)'s proprietary OVPENS technology platform, which has produced a portfolio including MVR-EX103 for skin-related conditions (INCI name granted in April 2025), EX104 for alopecia treatment, and EX105 for localized fat accumulation. These products are designed for direct commercialization with flexible registration pathways, targeting aging-related market segments while also advancing clinical therapeutic applications for chronic conditions such as wound healing and pulmonary fibrosis.
The engineered exosomes co-deliver multi-functional proteins with designed precise efficacy and enhanced skin penetration, enabling deep cellular-level modulation through non-invasive topical use. This approach represents a departure from traditional treatment paradigms by offering professional-grade bioactive solutions for home use.
Market Access and Commercial Potential
INCI certification functions as the universal "passport" for aesthetic ingredients, covering multiple major markets including the US, EU, and Japan. This certification validates ImmVira (搜索)'s pioneering position in engineered exosome technology, enables direct overseas market entry, and enhances consumer trust through INCI's mandated ingredient transparency requirements.
Market projections from Frost and Sullivan indicate significant commercial opportunities, with the global alopecia treatment market expected to reach $89.9 billion and the localized adipose accumulation management treatment market projected to reach $191.5 billion by 2033.
Strategic Vision and Platform Expansion
"From skin repair (EX103) to hair regeneration (EX104) and localized fat reduction (EX105), our OVPENS platform demonstrates sustainable capacity for breakthrough healthcare innovations," stated Dr. Zhou Guoying, CEO of ImmVira (搜索). "Leveraging precision-engineered design and targeted delivery of multiplex functional proteins, we maintain a strategically balanced portfolio that directly targets high-value, aging-related market opportunities with strong business acumen."
The platform's inherent expandability allows for rapid development of new pipeline candidates to address specific indication needs, enabling novel treatment modalities designed to help consumers achieve health and beauty goals. ImmVira (搜索) is accelerating development of a worldwide health and wellness product matrix spanning skin health, hair management and fat reduction.
Company Profile and Broader Pipeline
ImmVira (搜索) operates as a clinical-stage biotechnology company powered by proprietary biological engineering technology, dedicated to the discovery, development, manufacture and commercialization of novel oncolytic immunotherapies and engineered exosome therapies. The company maintains a risk-balanced product portfolio comprising both potentially best-in-class oncolytic immunotherapy candidates for solid tumors and innovative engineered exosome assets.
The company's strategic priority includes becoming a global leader in bladder cancer treatment development, advancing oncolytic immunotherapy candidates with high clinical potential. The engineered exosome assets are being accelerated through strategic, differentiated regulatory pathways to enable expedited commercialization and generate sustainable cash flows to fuel broader drug development efforts.